

500 Chipeta Way, Salt Lake City, Utah 84108-1221

phone: 801-583-2787, toll free: 800-522-2787

Jonathan R. Genzen, MD, PhD, Chief Medical Officer

Patient Age/Sex: 37 years Female

Specimen Collected: 20-Mar-23 14:26

Tgt drug prof, MassSpec/EMIT, UR, | Received: 23-Mar-23 14:29

Report/Verified: 23-Mar-23 15:47

Interp

Procedure	Result	Units	Reference Interval
Creatinine, Urine	100.9	mg/dL	[20.0-400.0]
Targeted drug profile Interp	See Note ⁱ¹		
DRUGS EXPECTED	See Interp		
Barbiturates (cutoff 200 ng/mL)	Not Detected		
Benzoyllecgonine (cutoff 150 ng/mL)	Not Detected		
Carisoprodol (cut-off 100 ng/mL)	Not Detected		
Ethyl Glucuronide (cutoff 500 ng/mL)	Present		
Marijuana Metabolite (cutoff 50 ng/mL)	Present		
Methadone (cutoff 150 ng/mL)	Not Detected		
PCP (cutoff 25 ng/mL)	Not Detected		
Tramadol (cutoff 100 ng/mL)	Not Detected		
6-acetylmorphine (cutoff 20 ng/mL)	Not Detected		
7-Aminoclonazepam (cutoff 40 ng/mL)	Present		
Alpha-OH-Alprazolam (cutoff 20 ng/mL)	Not Detected		
Alpha-OH-Midazolam (cutoff 20 ng/mL)	Not Detected		
Alprazolam (cutoff 40 ng/mL)	Not Detected		
Amphetamine (cutoff 50 ng/mL)	Not Detected		
Buprenorphine (cutoff 5 ng/mL)	Not Detected		
Clonazepam (cutoff 20 ng/mL)	Not Detected		
Codeine (cutoff 40 ng/mL)	Not Detected		
Diazepam (cutoff 50 ng/mL)	Not Detected		
Fentanyl (cutoff 2 ng/mL)	Not Detected		
Gabapentin (cutoff 3,000 ng/mL)	Present		
Hydrocodone (cutoff 40 ng/mL)	Present		
Hydromorphone (cutoff 20 ng/mL)	Present		
Lorazepam (cutoff 60 ng/mL)	Not Detected		
MDA (cutoff 200 ng/mL)	Not Detected		
MDEA-Eve (cutoff 200 ng/mL)	Not Detected		
MDMA-Ecstasy (cutoff 200 ng/mL)	Not Detected		
Meperidine metabolite (cutoff 50 ng/mL)	Not Detected		
Methamphetamine (cutoff 200 ng/mL)	Not Detected		

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-079-900246

Report Request ID: 17731679

Printed: 23-Mar-23 16:02

Page 1 of 3

Tgt drug prof, MassSpec/EMIT, UR, | Received: 23-Mar-23 14:29 Report/Verified: 23-Mar-23 15:47

Interp

Procedure	Result	Units	Reference Interval
Methylphenidate (cutoff 100 ng/mL)	Not Detected		
Midazolam (cutoff 20 ng/mL)	Not Detected		
Morphine (cutoff 20 ng/mL)	Not Detected		
Naloxone (cutoff 100 ng/mL)	Not Detected		
Norbuprenorphine (cutoff 20 ng/mL)	Not Detected		
Nordiazepam (cutoff 50 ng/mL)	Not Detected		
Norfentanyl (cutoff 2 ng/mL)	Not Detected		
Norhydrocodone (cutoff 100 ng/mL)	Present		
Noroxycodone (cutoff 100 ng/mL)	Not Detected		
Noroxymorphone (cutoff 100 ng/mL)	Not Detected		
Oxazepam (cutoff 50 ng/mL)	Not Detected		
Oxycodone (cutoff 40 ng/mL)	Not Detected		
Oxymorphone (cutoff 40 ng/mL)	Not Detected		
Phentermine (cutoff 100 ng/mL)	Not Detected		
Pregabalin (cutoff 3,000 ng/mL)	Not Detected		
Tapentadol (cutoff 100 ng/mL)	Not Detected		
Tapentadol-o-Sulf (cutoff 200 ng/mL)	Not Detected		
Temazepam (cutoff 50 ng/mL)	Not Detected		
Zolpidem (cutoff 20 ng/mL)	Not Detected		
Zolpidem Metabolite (cutoff 100 ng/mL)	Not Detected		
Targeted drug profile panel	See Below ⁱ²		
EER Tgt drug prof,MS/EMIT,UR, Interp	See Note ^{f1}		

Result Footnote

f1: EER Tgt drug prof, MS/EMIT, UR, Interp
Authorized individuals can access the ARUP
Enhanced Report using the following link:

Test Information

i1: Targeted drug profile Interp
INTERPRETIVE INFORMATION: Targeted drug profile Interp

Interpretation depends on accuracy and completeness of patient medication information submitted by client.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-079-900246

Report Request ID: 17731679

Printed: 23-Mar-23 16:02

Page 2 of 3

Test Information

i2: Targeted drug profile panel
Methodology: Qualitative Enzyme Immunoassay and Qualitative Liquid Chromatography-Tandem Mass Spectrometry, Quantitative Spectrophotometry

The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration must be greater than or equal to the cutoff to be reported as present. If specific drug concentrations are required, contact the laboratory within two weeks of specimen collection to request quantification by a second analytical technique. Interpretive questions should be directed to the laboratory.

Results based on immunoassay detection that do not match clinical expectations should be interpreted with caution. Confirmatory testing by mass spectrometry for immunoassay-based results is available, if ordered within two weeks of specimen collection. Additional charges apply.

For medical purposes only; not valid for forensic use.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab

Unless otherwise indicated, testing performed at:

ARUP Laboratories

500 Chipeta Way, Salt Lake City, UT 84108

Laboratory Director: Jonathan R. Genzen, MD, PhD

ARUP Accession: 23-079-900246

Report Request ID: 17731679

Printed: 23-Mar-23 16:02